Please check your internet connection and try again.
# Technivie (تلaprevir)
## Overview
Technivie (telaprevir) is a protease inhibitor used in combination therapy for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection. It is no longer recommended for use due to the availability of more effective and safer treatment options.
## Primary Indications
Treatment of chronic hepatitis C virus (HCV) genotype 1 infection in treatment-naive adults with compensated liver disease.
## Adult Dosing
Telaprevir was dosed as **1125 mg every 8 hours** (three times daily) in combination with pegylated interferon alfa and ribavirin.
The duration of treatment was typically 24 weeks, followed by 24 weeks of pegylated interferon alfa and ribavirin alone, for a total of 48 weeks.
## Pediatric Dosing
Pediatric dosing information is not established for telaprevir.
## Dose Adjustments
Dose reductions or discontinuation were recommended based on the severity of adverse events, particularly skin reactions and hematologic toxicities. Specific dose adjustment guidelines were complex and dependent on the specific adverse event.
## Contraindications
* Known hypersensitivity to telaprevir or any of its excipients.
* Use in patients with moderate to severe hepatic impairment.
* Concomitant use with certain drugs that are moderate or strong CYP3A4 inhibitors or substrates with a narrow therapeutic index.
## Adverse Effects
* **Common:** Rash (including severe forms like Stevens-Johnson syndrome and toxic epidermal necrolysis), pruritus, fatigue, nausea, diarrhea, anemia, neutropenia, dysgeusia.
* **Serious:** Severe skin reactions, hypersensitivity reactions, gastrointestinal bleeding, worsening anemia.
## Key Drug Interactions
Telaprevir is a moderate inhibitor of CYP3A4 and P-glycoprotein. Concomitant use with drugs metabolized by these pathways could lead to increased drug concentrations and potential toxicity.
* **Avoid concomitant use with:** Certain statins (e.g., simvastatin, atorvastatin), benzodiazepines (e.g., midazolam), certain calcium channel blockers, and other protease inhibitors.
* **Caution with:** Drugs that can prolong the QT interval.
* **Reduced efficacy with:** Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin).
## Monitoring
* HCV RNA levels (viral load) throughout treatment.
* Complete blood counts (CBC) with differential.
* Liver function tests (LFTs).
* Skin examinations for rash.
* Renal function.
## Clinical Pearls
* Telaprevir is **no longer recommended** for the treatment of hepatitis C due to lower efficacy and higher toxicity compared to newer direct-acting antiviral (DAA) regimens.
* The risk of severe skin reactions was significant and required vigilant monitoring.
* Combination therapy was essential; telaprevir monotherapy is ineffective and can lead to resistance.
***
**Disclaimer:** This information is intended for healthcare professionals and is based on available data at the time of generation. It is crucial to consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions, as drug information can change.
